Fischer Medical Ventures Limited: AGM Resolutions Passed, Dividend Declared
Fischer Medical Ventures Limited's 33rd AGM on September 29, 2026, saw all resolutions passed. Shareholders approved the FY26 financial statements and a 5% dividend (₹0.05 per share). Ms. Svetlana Rao Raviwada was re-appointed as Director, and Mr. David Yeow was appointed as Independent Director for five years.
The passing of resolutions related to financial statements, dividend, and director appointments are routine yet important corporate actions that impact governance and shareholder returns, warranting a medium impact.
The announcement reports the successful passing of all resolutions at the AGM, including the approval of financial statements and dividend declaration, which are positive outcomes for the company and its shareholders.
Fischer Medical Ventures Limited announced the results of its 33rd Annual General Meeting (AGM), held on Tuesday, September 29, 2026, through Video Conferencing / Other Audio-Visual Means. All resolutions presented at the AGM were duly passed by the shareholders.
The resolutions included the adoption of the Audited Standalone and Consolidated Financial Statements for the financial year ended March 31, 2026. A dividend of 5% per Equity Share (₹0.05 per equity share of ₹1/- each) for the financial year ended March 31, 2026, was also declared.
Furthermore, Ms. Svetlana Rao Raviwada was re-appointed as a Director retiring by rotation. The shareholders also approved the appointment of Mr. David Yeow as an Independent Director for a term of five years, commencing from September 3, 2026, to September 2, 2031.
The voting process, which included remote e-voting from September 26 to September 28, 2026, and e-voting during the AGM, was scrutinized by M/s. Nuren Lodaya and Associates. The report confirmed that all resolutions were passed with the requisite majority.
What to do with a filing like this
Fischer Medical Ventures Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Fischer Medical Ventures Limited. Read the original for the full detail.